All timings are in SGT (UTC +8). Click here to convert to your timezone »
Day 1: 23 September 2020 | Wednesday
Opening Plenary
13:00
KEYNOTE ADDRESS:
From Cancer to COVID-19: Balancing Short & Long Term Corporate Goals, Engaging in New Collaborations & Building the Future of Digital Pharma
Dr. Andreas Schmidt, Chief Executive Officer, Proteona, Singapore/Germany
13:30
PHARMA LEADERS’ THINK TANK:
Redefining Pharma’s Role in the Global Healthcare Reform Agenda
- COVID-19 vaccines candidate development
- Regulations on pandemic drugs approval and accelerated clinical trials under diverse regimes
- Future of pricing and affordability for Novel Drugs
- Why technology should be the key component to surviving COVID-19?
- AI and its immense potential in use of pandemic treatments and early detection
Moderator:
Christine Kuan, Board Director, Taiwan Cognitive Enhancement Association, Taiwan
Panellists:
Dr. Sucharita Das, Chief Consultant Regulatory, Quality and Clinical Trials Global/ APAC, Singapore
Edsel Pereira, Group Vice President – Information Technology, Glenmark Pharmaceuticals, India
Alexander Zach, Senior Vice President , Global Head of Market Access , Policy and Pricing , Biocon Biologics Ltd
Dr. Keith Carpenter, A*STAR Senior Fellow, Pharma Innovation Programme Singapore (PIPs), Singapore
14:30
Online Networking and Stretch Break
COVID-19 Impacts on Pricing and Access
15:00
Chairperson’s Opening Remarks
Christine Kuan, Board Director, Taiwan Cognitive Enhancement Association, Taiwan
15:00
COVID-19 Response Dialogue: Accelerating Speed to Market, Drug Accessibility and Affordability
- Assessing regulator’s priority, managing delays and disruption on appraisals
- Not so new normal: Impediments to commercialising drugs at the same speed and scale
- Donation and pricing commitments from pharma manufacturers
- Developments in Government pricing and reimbursement
- How will pharma price the affordable therapeutics against COVID-19?
Moderator:
Alexander Zach, Senior Vice President , Global Head of Market Access , Policy and Pricing , Biocon Biologics Ltd
Panellists:
Yelitte Ho, Manager, Access and Funding Policy, Medicines Australia, Australia
Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan
Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore
15:45
Managing the Effects of COVID-19 on Drug Access
- Propagating international access for drugs
- Improving access for high cost drugs – will it be the case for coronavirus treatments? -Creating innovative value
- Overcoming access difficulties in regions
Alexander Zach, Senior Vice President , Global Head of Market Access , Policy and Pricing , Biocon Biologics Ltd
16:15
Online Networking & Stretch Break
16:30
Agile Marketing in the era of COVID-19
- Redefine, transform and innovate pharma business strategy for greater access
- Adjusting commercial models- patient-physician relationships
- Catering to high population markets
Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan
17:00
Personalized Healthcare – Enabling a Next Generation Healthcare Ecosystem to Accelerate Patient Access in Singapore
Jek Fong, Director, Market Access and Personalised Healthcare, Roche, Singapore
17:30
Changing Regional Landscapes towards Digitalisation and what it means for Access
Reswita Gisriani, Chair of Cluster 1 Market Access Council, Medtronic, Indonesia
18:00
Chairperson’s Summary and End of Day 1
Day 2: 24 September 2020 | Thursday
Agile Market Access
13:00
Chairperson’s Opening Remarks
Christine Kuan, Board Director, Taiwan Cognitive Enhancement Association, Taiwan
13:00
Dealing with COVID-19 and Drug Access in Indonesia
- Managing access and supply disruption for usual drugs
- Local in-ward looking policy trends and the impacts
- Prioritising local manufacturing and suppliers
Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia
13:30
Shifting Mindsets: Increasing Access Sustainably in LMICs with Limited Public Funding
- Development of locally-tailored access solutions balancing access and sustainability
- Scaling innovative access approaches for specialized, high-cost treatments
- The role of multi-stakeholder partnerships in ensuring sustainability
- Facilitating the patient experience through digital tools
- Case study: Maximizing medical benefit through Patient Support Programs
Roshel Jayasundera, Director, Global Consulting, Axios International, Dubai
14:00
Fair Pricing and Drug Affordability Whilst Satisfying Governments Healthcare Policy
- ASEAN and Asia market analysis
- Working with different reimbursement regimes – Aiming for a Win-Win situation
- Managing drug development costs, investments and ROIs
- Improving drug access and copayment- What is the right balance?
- Developed vs emerging market landscapes: What are the key considerations for growth
Moderator:
Jun Feng, Market Access Associate Director, Oncology, JAPAC, AbbVie, Singapore
Panellists:
Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia
Judy Deng, Head of Market Access, Oncology, Novartis, China
Rizman Abudaeri, Director, Market Access, Government and Regulatory Affair, AstraZeneca, Indonesia
14:55
Regenerative Medicine Part 1: Pricing and Market Access in Japan and SEA
Co-Presenters:
Neal Somchand, Principal and Head of Japan, Deallus Consulting, Tokyo
Phoebe Lam, Consultant, Deallus Consulting
15:25
Online Networking and Stretch Break
15:35
China’s Drug Landscape – The Medical Insurance Reform of Tripartite System and Implications for Market Access
- Access for innovative therapies in China
- Practical considerations and negotiations for placement onto the list of National Reimbursement Drug List (NRDL)
- Proving value for innovative therapies and medical insurance
- China case study: Managing access for cancer drugs post COVID-19 outbreak
Judy Deng, Head of Market Access, Oncology, Novartis, China
16:00
Regenerative Medicine Part 2: Pricing and Market Access in Australia and China
Co-Presenters:
Helen Cunliffe, Senior Consultant and Australia Lead, Deallus Consulting, Australia
Flora Tian, China Office Lead, Deallus Consulting, Shanghai
16:30
Oncology and COVID-19: Challenges and Opportunities
- Building access to cancer care in emerging markets
- Building portfolio and connecting with customers
- Using digital tools and access strategies
Anupama Rao Singh, Business Head – LATAM | Head – Oncology and Institutional Business COE, Dr.Reddy’s Emerging Markets
17:00
Chairperson’s Summary and End of Day 2
Day 3: 25 September 2020 | Friday
Payer and Reimbursement
13:00
Chairperson’s Opening Remarks
Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan
13:00
Case Study:
Lundbeck’s Value Creation Strategies in Asia
- Working with payers, patients and reimbursement bodies for creating customer-focused values
- Value creation for disease area of psychiatry
- Lowering stigma for treatments in neurology and psychiatry
Viviendouf Koh, Regional Marketing Director, South and East Asia, Lundbeck, Singapore
13:30
Australia Case Study:
COVID-19 Government, Reimbursement & Regulatory Updates
- COVID-19 in Australia
- Universal access to healthcare in Australia and the Pharmaceutical Benefits Scheme (PBS)
- Universal Subsidy Scheme for Medicines
- How does a drug get listed on the PBS (registration process, pricing, listing consideration)?
- Key factors influencing decision making by the independent Pharmaceutical Benefits Advisory Committee
- Patent and data protection of pharmaceuticals in Australia
Yelitte Ho, Manager, Access and Funding Policy, Medicines Australia, Australia
Optimising RWE and HTA
14:00
Demonstrating Value and Data Gathering for RWE in Asia
- Understand how RWE is different from randomized control trials (RCTs)
- How do Regulatory bodies consider the use of RWE for decision making?
- Challenges to collect RWE; how to access and when to use do we have that ready in Asia
- Successful regional case studies
Kim Soyoung, Director HEOR, Medical Affairs, Asia & Oceania, Astellas Pharma, Singapore
14:30
Online Networking and Stretch Break
15:00
Use of Real-World Evidence in the Drug Registration Process
- What’s real World Data, Real world Evidence?
- How is Real World Evidence generated?
- Overview of Regulations (US FDA, EMA, China NMPA)
Gaelle Richer, Director Global Regulatory Affairs, GSK, Singapore
15:30
HTA for Growing Economies
- Challenges and Opportunities of using HTA
- Key areas of focus for emerging markets
- Maximising the returns of HTA on proving drug value
Nathan K, Market Access and Government Affairs Director, Johnson & Johnson, Malaysia
16:00
Online Networking and Stretch Break
Diversity and Inclusion in Pharma
16:20
Cultivating the Next-Gen of Women Leaders in Pharma
- Why does gender equality matter on the board?
- Key challenges facing women leaders in Pharma
- Management efforts to address some of these challenges, and remaining gaps
- Reflections on the journey to the top
- Breaking the glass ceiling: Lessons learnt along the way, and advice to my younger self
- Management efforts to address some of these challenges, and remaining gaps
Moderator:
Sayantani Dasgupta, Former Associate Director, Customer Engagement Strategy & Commercial Excellence, MSD, Japan
Panelists:
Anupama Rao Singh, Business Head – LATAM | Head – Oncology and Institutional Business COE, Dr.Reddy’s Emerging Markets, Dr Reddys, India
Angela Brady, Director of Innovation Research, APAC R&D, GSK, Singapore
Chandana Yeluri, Head- Digital and Continuous Improvement, Sandoz Development Center, Novartis, India
More panelists to be confirmed
17:10
End of Digital Conference Day 3